New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
09:03 EDTATRS, DCTHAntares Pharma announces resignation of CEO Wotton, names Hobbs as CEO
Antares Pharma (ATRS) announced the resignation of Paul K. Wotton, Ph.D. who informed the companys Board of Directors that he will assume the position of CEO of a development stage biotechnology company. Wotton also has resigned from the Antares Board of Directors. Antares Pharma also announced today the appointment of Eamonn P. Hobbs to the position of President and CEO of the company effective immediately. Hobbs joined the Antares Board of Directors in August 2009 and has over 30 years of experience in the pharmaceutical, medical device, and combination products industry, including the medical specialty fields of radiology, vascular surgery, interventional cardiology, oncology and gastroenterology. Hobbs was previously the President and CEO of Delcath Systems (DCTH).
News For ATRS;DCTH From The Last 14 Days
Check below for free stories on ATRS;DCTH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
13:05 EDTDCTHLinkedto says $3 per share bid for Delcath Systems dropped
Subscribe for More Information
September 15, 2014
10:33 EDTDCTHLinkedto says two public companies interested in Delcath Systems
Subscribe for More Information
07:06 EDTDCTHDelcath Systems appoints Dr. Jennifer Simpson as Interim-CEO
Delcath Systems announced the reorganization of the company's leadership as Dr. Jennifer Simpson has been appointed interim president and interim CEO. Dr. Simpson has served as interim co-president and interim Co-CEO of Delcath since September 2013. Dr. Graham Miao, who has served as interim co-president, interim Co-CEO and CFO will be leaving the company at the end of September to pursue other opportunities. Barbra Keck, currently vice president, Controller & Principal Accounting Officer will assume the responsibilities of Principal Financial Officer. In addition, Dr. Roger G. Stoll, who has been a member of the Delcath board since 2008, has been appointed to the newly created position of Executive Chairman. He succeeds Gabriel Leung, who is stepping down from his position as chairman. Leung will remain on the Board, but his schedule demands inhibited his ability to continue as chairman.
07:01 EDTATRSAntares Pharma names Robert Apple as COO, effective immediately
Subscribe for More Information
September 9, 2014
12:52 EDTDCTHLinkedto raises unsolicited bid for Delcath Systems to $3.00 per share
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use